Currently, phase I trials for another three OVs are ongoing against melanoma, namely, ONCOS (adeno ∆24-RGD-GM-CSF insertion) (NCT03003676), herpes virus OrienX010 (NCT03048253), and ICOVIR-5 (NCT01864759) (Table 2). This evidence concerns the gene CSF2 and melanoma.